Table 1.
Size Analysis by Dynamic Light Scattering for the Test and the Control LNs
| lipid composition (molar percentage) | encapsulated content | size (nm) ± std dev | PDI ± std dev | |
|---|---|---|---|---|
| DSPC | DSPC (100) | gemcitabine | 178 ± 3.6 | 0.15 ± 0.02 |
| Test LNs | POPE-azobenzene-PEG (50): | gemcitabine | 180 ± 3.4 | 0.23 ± 0.01 |
| DSPC (39): | ||||
| DSPE-PEG-iRGD (10): | ||||
| Lissamine rhodamine (1) | ||||
| LNs without iRGD | POPE-AZB-PEG (50): | gemcitabine | 121 ± 1.5 | 0.12 ± 0.01 |
| DSPC (49): | ||||
| Lissamine rhodamine (1) | ||||
| Test LNs | POPE-AZB-PEG (50): | carboxyfluorescein | 235 ± 2.3 | 0.20 ± 0.04 |
| DSPC (40): | ||||
| DSPE-PEG-iRGD (10): |